Enovis Corporation · NYSE:ENOV
Enovis — Investor Presentation (September 2023)
11 slides from Enovis's investor presentation, Sep 12, 2023
Slide 1: Enovis presentation – CEO Matt Trerotola and CFO Ben Berry
Exhibit 99.1 Matt Trerotola Chief Executive Officer Ben Berry Chief Financial Officer
Slide 2: Forward-looking Statements and Non-GAAP Financial Information
Forward-looking Statements Non-GAAP Financial Information This presentation includes forward-looking statements, including Enovis has provided in this presentation financial information that has not been prepared in accordance with accounting forward-looking statements within the meaning of the U.S.
Slide 3: Enovis: An Innovation and Growth driven MedTech company
Enovis: An Innovation and Growth driven MedTech company Financial Profile – 2023 Guidance Strategic Financial Goals Sales aEBITDA High Single Digit Growth $1.7B $262-270mm DD Reconstructive (Recon) + MSD Prevention & Recovery (P&R) growth Sales Mix by Geography & Segment $2B+ in Sales by 2024 ROW 5%
Slide 4: Addressing a Large and Attractive Market
Addressing a Large and Attractive Market Enovis competes in half of the $53B Market Growth Trends Provide Runway Orthopedics market and “touches” nearly all Est. Market Growth Rate Our Recon served markets ~4% $48B $5B Aging but active population, Knee 9 rising obesity 3-4% Hip 8 Extremities 3 7-8%
Slide 5: Established Brands and Accelerating Innovation
Established Brands and Accelerating Innovation Reconstructive Segment Prevention & Recovery Segment Foot & Ankle Footcare Other Shoulder ~$0.6B Recovery Bracing ~$1.1B 1 TTM 1 Sciences TTM Hip Knee #1 #1 #2 #3 DD Globally Globally In Bone In US Organic Growth in Bracing in Rehab Stimulation Shoulder
Slide 6: Uniquely Positioned Across Full Ortho Care Continuum
Uniquely Positioned Across Full Ortho Care Continuum PREVENTION REPAIR RECOVERY PERFORMANCE PREVENTION SURGICAL RECOVERY REHAB • Athletic braces• Off-loading braces• Shoulders• Post-op braces• Electrotherapy • Back braces• Walker boots • Muscle stimulation• Knees• Laser therapy • Cold therapy• Cold
Slide 7: Expanding Margins with Clear Strategy & Business System
Expanding Margins with Clear Strategy & Business System aEBITDA Margin (%) Margin Drivers >50bps per year • Mix benefits generated by growth in Recon • Scale and synergy from recent acquisitions • Operating leverage from growth, productivity, and disciplined price/cost management 2022 Mix Acquisitio
Slide 8: Robust M&A Opportunities to Accelerate Growth
Robust M&A Opportunities to Accelerate Growth Expand Expand along Redefine boundaries Continuum of Care Enter Logical Clinic- Based Adjacencies Extend Build out from core Expand Geographically Add High-Growth / Apply Technology in High-Margin P&R Other Markets Build around Healthcare Provider Add Di
Slide 9: Recent Recon Acquisitions Enhancing Growth Profile
Recent Recon Acquisitions Enhancing Growth Profile Recon Extremities Foot & Ankle Platform Globalization Expansion 1 Pre- 2023e Established a strong portfolio across Foot & Ankle Acquisition (Yr. 2) Growth MSD DD Gross ~55% ~60% Margin aEBITDA HSD High Teens Margin • Globalized surgical business in
Slide 10: Full Year 2023 Outlook
Full Year 2023 Outlook February May August Comments Organic Sales Growth 5-6% (cc) 6-7% (cc) 7-7.5% (cc) • Increased full year growth and profit outlook aEBITDA $255-$265mm $259-$267mm $262-$270mm • Sales outlook including recent ~$85mm ~$85mm ~$85mm Depreciation acquisitions: • ~$1.7b total Enovis
Slide 11: enovis. Creating Better Together
enovis. Creating Better Together™